Visual Rating and Computer-Assisted Analysis of FDG PET in the Prediction of Conversion to Alzheimer's Disease in Mild Cognitive Impairment

Molecular Diagnosis & Therapy
Jae Myeong KangDong Young Lee

Abstract

Fluorodeoxyglucose (FDG) positron emission tomography (PET) is useful to predict Alzheimer's disease (AD) conversion in patients with mild cognitive impairment (MCI). However, few studies have examined the extent to which FDG PET alone can predict AD conversion and compared the efficacy between visual and computer-assisted analysis directly. The current study aimed to evaluate the value of FDG PET in predicting the conversion to AD in patients with MCI and to compare the predictive values of visual reading and computer-assisted analysis. A total of 54 patients with MCI were evaluated with FDG PET and followed-up for 2 years with final diagnostic evaluation. FDG PET images were evaluated by (1) traditional visual rating, (2) composite score of visual rating of the brain cortices, and (3) composite score of computer-assisted analysis. Receiver operating characteristics (ROC) curves were compared to analyze predictive values. Nineteen patients (35.2%) converted to AD from MCI. The area under the curve (AUC) of the ROC curve of the traditional visual rating, composite score of visual rating, and computer-assisted analysis were 0.67, 0.76, and 0.79, respectively. ROC curves of the composite scores of the visual rating and computer-a...Continue Reading

References

Aug 13, 1998·Journal of Neural Transmission. Supplementum·R Mielke, W D Heiss
Nov 22, 2001·JAMA : the Journal of the American Medical Association·D H SilvermanM E Phelps
Apr 8, 2004·Radiology·Meenal B PatwardhanOlivier T Rutschmann
Aug 21, 2004·International Psychogeriatrics·Maddalena Bruscoli, Simon Lovestone
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
Jul 24, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Flavio NobiliMarco Pagani
Oct 18, 2008·International Review of Psychiatry·Ricardo F AllegriHerman Buschke
Aug 8, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Silvia MorbelliFlavio Nobili
Dec 17, 2009·Archives of Neurology·Ronald C PetersenClifford R Jack
Jun 12, 2010·American Journal of Alzheimer's Disease and Other Dementias·Robert LaforceRémi W Bouchard
Jul 2, 2010·Neurology·S M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Oct 5, 2010·International Journal of Alzheimer's Disease·James C PattersonJames B Pinkston
May 5, 2011·Expert Review of Neurotherapeutics·Aron S Buchman, David A Bennett
Jun 10, 2011·The New England Journal of Medicine·Ronald C Petersen
Nov 21, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Rik OssenkoppeleBart N M van Berckel
Dec 13, 2012·Radiology·Jennifer L ShafferUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
May 30, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Javier ArbizuUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 31, 2013·Neurology·Giovanni B FrisoniUNKNOWN ISTAART's NeuroImaging Professional Interest Area
Nov 2, 2013·NeuroImage. Clinical·Jonathan YoungUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 16, 2015·Journal of Alzheimer's Disease : JAD·Kengo ItoUNKNOWN SEAD-J Study Group
Jan 30, 2015·The Cochrane Database of Systematic Reviews·Nadja SmailagicChristos Sachpekidis
Nov 21, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Timo GrimmerAlexander Kurz
Dec 30, 2015·Proceedings of the National Academy of Sciences of the United States of America·Valentin RiedlChristian Sorg

❮ Previous
Next ❯

Software Mentioned

SPSS
Statistical Parametric Mapping ( SPM )
MedCalc
SPSS Statistics
Matlab
PALZ
SPM8

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.